254 related articles for article (PubMed ID: 30647797)
21. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.
Vaughan CA; Singh S; Grossman SR; Windle B; Deb SP; Deb S
Mol Oncol; 2017 Jun; 11(6):696-711. PubMed ID: 28423230
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
23. Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.
Bat-Erdene A; Miki H; Oda A; Nakamura S; Teramachi J; Amachi R; Tenshin H; Hiasa M; Iwasa M; Harada T; Fujii S; Sogabe K; Kagawa K; Yoshida S; Endo I; Aihara K; Abe M
Oncotarget; 2016 Nov; 7(48):79064-79075. PubMed ID: 27738323
[TBL] [Abstract][Full Text] [Related]
24. Biallelic TP53 gain of function mutations in rapidly progressing solid tumors.
Sande CM; Chang B; Monga V; Bossler AD; Ma D
Cancer Genet; 2018 Apr; 222-223():20-24. PubMed ID: 29666004
[TBL] [Abstract][Full Text] [Related]
25. TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer.
Koul A; Bendahl PO; Borg A; Fernö M; Lidebring MF; Högberg T; Einarsson EL; Ridderheim M; Willén R
Int J Gynecol Cancer; 2002; 12(4):362-71. PubMed ID: 12144684
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
Gilardini Montani MS; Granato M; Santoni C; Del Porto P; Merendino N; D'Orazi G; Faggioni A; Cirone M
Cell Oncol (Dordr); 2017 Apr; 40(2):167-180. PubMed ID: 28160167
[TBL] [Abstract][Full Text] [Related]
27. A dominant-negative effect drives selection of
Boettcher S; Miller PG; Sharma R; McConkey M; Leventhal M; Krivtsov AV; Giacomelli AO; Wong W; Kim J; Chao S; Kurppa KJ; Yang X; Milenkowic K; Piccioni F; Root DE; Rücker FG; Flamand Y; Neuberg D; Lindsley RC; Jänne PA; Hahn WC; Jacks T; Döhner H; Armstrong SA; Ebert BL
Science; 2019 Aug; 365(6453):599-604. PubMed ID: 31395785
[No Abstract] [Full Text] [Related]
28. Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?
Oduah EI; Grossman SR
Cancer Biol Ther; 2020 Apr; 21(4):293-302. PubMed ID: 32041464
[TBL] [Abstract][Full Text] [Related]
29. Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells.
Yoshikawa K; Hamada J; Tada M; Kameyama T; Nakagawa K; Suzuki Y; Ikawa M; Hassan NM; Kitagawa Y; Moriuchi T
Biomed Res; 2010 Dec; 31(6):401-11. PubMed ID: 21187651
[TBL] [Abstract][Full Text] [Related]
30. Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation.
Seo SK; Hwang CS; Choe TB; Hong SI; Yi JY; Hwang SG; Lee HG; Oh ST; Lee YH; Park IC
Oncotarget; 2015 Sep; 6(28):26528-40. PubMed ID: 25605253
[TBL] [Abstract][Full Text] [Related]
31. Triptolide promotes degradation of the unfolded gain-of-function Tp53
Zhou J; Luo J; Li P; Zhou Y; Li P; Wang F; Mallio CA; Rossi G; Jalal AH; Filipovic N; Tian Z; Zhao X
Transl Lung Cancer Res; 2022 May; 11(5):802-816. PubMed ID: 35693277
[TBL] [Abstract][Full Text] [Related]
32. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.
Zhu J; Sammons MA; Donahue G; Dou Z; Vedadi M; Getlik M; Barsyte-Lovejoy D; Al-awar R; Katona BW; Shilatifard A; Huang J; Hua X; Arrowsmith CH; Berger SL
Nature; 2015 Sep; 525(7568):206-11. PubMed ID: 26331536
[TBL] [Abstract][Full Text] [Related]
33. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
34. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.
Hanel W; Marchenko N; Xu S; Yu SX; Weng W; Moll U
Cell Death Differ; 2013 Jul; 20(7):898-909. PubMed ID: 23538418
[TBL] [Abstract][Full Text] [Related]
35. Mutant p53 gain of function induces HER2 over-expression in cancer cells.
Román-Rosales AA; García-Villa E; Herrera LA; Gariglio P; Díaz-Chávez J
BMC Cancer; 2018 Jul; 18(1):709. PubMed ID: 29970031
[TBL] [Abstract][Full Text] [Related]
36. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
37. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
38. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.
Seo SK; Jin HO; Woo SH; Kim YS; An S; Lee JH; Hong SI; Lee KH; Choe TB; Park IC
J Thorac Oncol; 2011 Aug; 6(8):1313-9. PubMed ID: 21642861
[TBL] [Abstract][Full Text] [Related]
40. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]